• Cefazedone: An Assay-to-Clinic Evidence Map

  2026-08-27

  Cefazedone (Refosporen) is best understood through an assay-to-clinic framework linking PBP-mediated cell-wall inhibition, susceptibility testing, and exposure above MIC. This article explains how the CAP pharmacokinetic study can improve experimental design while clarifying its translational limits.

• Gamithromycin: From PK/PD to Assay Design

  2026-08-27

  Gamithromycin research is strongest when exposure, biological matrix, and pharmacodynamic endpoints are interpreted together. This evidence-led guide uses ML-1709460 pharmacology and a foundational PK review to build more defensible respiratory infection assays.

• Hyaluronic Acid Sodium Salt in siRNA Translation

  2026-08-26

  A translational analysis of how Hyaluronic acid sodium salt functions as an extracellular matrix component and delivery interface, informed by a preclinical study of HA-coated siRNA nanoparticles targeting TDRD9 in Pseudomonas aeruginosa lung injury.

• ML-Guided LNPs for Microglia mRNA Delivery

  2026-08-26

  Rafiei, Shojaei, and Chau developed a machine learning workflow to identify lipid nanoparticles that both deliver mRNA and influence inflammatory microglial phenotypes. Their HA-LNP2 formulation delivered IL10 mRNA, reduced inflammatory readouts in activated microglia, and showed activity in human iPSC-derived microglia, while also revealing the importance of immune-state-specific model validation.

• Omega-3 PUFAs Protect Neonatal Mice from Sevoflurane

  2026-08-25

  A 2026 Molecular Neurobiology study links repeated neonatal sevoflurane exposure to impaired glymphatic transport, phosphorylated tau accumulation, mitochondrial dysfunction, and later cognitive and fine motor deficits. Maternal omega-3 polyunsaturated fatty acid supplementation preserved AQP4 polarization through PDGF-B/PDGFRβ signaling and reduced downstream neurotoxicity, providing a mechanistic framework for studying anesthetic-associated developmental injury.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine

  2026-08-25

  Use this DMSO-compatible α2-adrenergic receptor agonist to connect receptor pharmacology with immune-context experiments, including post-resection osteosarcoma recurrence models. The workflow emphasizes vehicle control, immune-competent comparisons, hydrogel compatibility, and orthogonal readouts rather than assuming direct tumor-cell killing.

• RESTRICT-seq Maps Epigenetic SCC Resistance

  2026-08-24

  The RESTRICT-seq preprint introduces a time-gated CRISPR screening framework for resolving when genetic dependencies emerge during squamous cell carcinoma resistance. Its findings support a dynamic view of epigenetic vulnerability, showing why resistance-associated dependencies may be missed by conventional endpoint screens and how temporal perturbation can improve cancer biology research.

• Nelfinavir Mesylate: HIV-1 Protease Inhibitor

  2026-08-23

  Nelfinavir Mesylate is an orally bioavailable HIV-1 protease inhibitor with nanomolar biochemical and cellular activity. Product data support its use in HIV infection research, while a 2025 study identifies nelfinavir as a chemical inhibitor of DDI2 that can sensitize cells to ferroptosis.

• B7H3×CD3 BiTE mRNA-LNPs in Cancer Therapy

  2026-08-22

  Huang and colleagues developed an ionizable lipid nanoparticle system for delivering mRNA encoding a B7H3×CD3 bispecific T-cell engager. Their study shows that one intravenous administration can generate substantial in vivo BiTE expression, extend its effective half-life, and produce durable antitumor activity in models of hematologic malignancy and melanoma.

• Gepotidacin: Mechanism and Research Benchmarks

  2026-08-21

  Gepotidacin, also known as GSK2140944, is a first-in-class triazaacenaphthylene inhibitor of bacterial DNA gyrase and topoisomerase IV. Its distinct cleavage mechanism and reported activity against selected fluoroquinolone-resistant bacteria make it a useful research tool for antibacterial and antibiotic resistance studies.

• AT13387: Hsp90 Inhibition in Cell Death Assays

  2026-08-20

  AT13387 is a potent Hsp90 inhibitor for dissecting client-protein loss, cell-cycle control, and apoptosis in cancer biology research. This article uses a recent norovirus–NINJ1 study to show how assay design can distinguish regulated secretion, apoptotic signaling, and terminal membrane rupture without conflating unrelated mechanisms.

• Dual Luciferase Reporter Gene System for SlSLAH1

  2026-08-20

  Use the Dual Luciferase Reporter Gene System to convert promoter, transcription-factor, and stress-response hypotheses into normalized same-sample measurements. This workflow translates the SlSTOP1–SlSZP1–SlSLAH1 mechanism into practical reporter design while preserving clear limits around mammalian-cell compatibility and plant validation.

• TaqI Restriction Endonuclease Protocol Guide

  2026-08-19

  TaqI Restriction Endonuclease provides rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA at the 5′-TCGA-3′ recognition site. It is intended for research workflows involving fast digestion and sticky-end generation, not diagnostic, clinical, or medical use.

• Baicalin Methyl Ester for Intestinal Barrier Studies

  2026-08-19

  Baicalin methyl ester provides a practical framework for studying LPS-driven epithelial injury, cytokine release, and tight-junction failure in MODE-K cells and mouse models. This guide translates its reported P65/TNF-α/MLCK/ZO-1 activity into assay-ready workflows, dose selection, and troubleshooting decisions.

• BOP Reagent for Peptide Coupling Workflows

  2026-08-18

  BOP reagent provides a practical route to carboxyl group activation, amide bond formation, and phenyl ester preparation in research-scale peptide workflows. This guide connects reaction setup and troubleshooting with a carrier-free prodrug study, while clearly separating established chemistry from translational opportunities.

458 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page